

## Publications by Justin Wilkins

1. Wilder-Smith C, Hill L, Wilkins JJ, Denny L. Effects of Morphine and Tramadol on Somatic and Visceral Sensory Function and Gastrointestinal Motility after Abdominal Surgery. *Anesthesiology*, 1999; 91(3):639-47
2. Wilkins JJ, Folb PI, Valentine N, Barnes KI. An economic comparison of chloroquine and sulfadoxine-pyrimethamine as first-line treatment for malaria in South Africa: development of a model for estimating recurrent direct costs. *Trans R Soc Trop Med Hyg*. 2002 Jan-Feb;96(1):85-90.
3. Langdon G, Wilkins J, Smith P & McIlleron H. Consecutive-dose pharmacokinetics of rifapentine in patients diagnosed with pulmonary tuberculosis. *International Journal of Tuberculosis and Lung Disease* 2004; 8(7):862-7.
4. Langdon G, Wilkins JJ, McFadyen L, McIlleron H, Smith PJ, Simonsson USH. Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients. *Antimicrobial Agents and Chemotherapy* 2005; 49(11):4429-36.
5. Wilkins JJ. NONMEMory: A run management tool for NONMEM. *Computer Methods and Programs in Biomedicine* 2005; 78(3):259-67.
6. Wilkins JJ, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson USH. Variability in the population pharmacokinetics of pyrazinamide in South African tuberculosis patients. *European Journal of Clinical Pharmacology* 2006 Sep;62(9):727-35.
7. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semimechanistic model to describe variable absorption. *Antimicrobial Agents and Chemotherapy* 2008; 52(6):2138-48.
8. Baverel PG, Savic RM, Wilkins JJ, Karlsson MO. Evaluation of the nonparametric estimation method in NONMEM VI: application to real data. *Journal of Pharmacokinetics and Pharmacodynamics* 2009; 36(4):297-315
9. Karlsson KE, Wilkins JJ, Jonsson F, Zingmark PH, Karlsson MO & Jonsson EN. Modeling disease progression in acute stroke using clinical assessment scales. *The AAPS Journal* 2010; 12(4), 683-691.
10. Wilkins JJ, Langdon G, McIlleron H, Pillai GC, Smith PJ & Simonsson US. Variability in the population pharmacokinetics of isoniazid in South African tuberculosis patients. *British Journal of Clinical Pharmacology*, 2011; 72(1): 51-62.
11. Joerger, M, Wilkins J, Fagagnini S, Baldinger R., Brenneisen R, Schneider U, et al. Single-dose Pharmacokinetics and Tolerability of Oral Delta-9-Tetrahydrocannabinol in Patients with Amyotrophic Lateral Sclerosis. *Drug Metabolism Letters*, 2012; 6(2), 102-108.
12. Matsushima S, Matthews I, Woessner R, Pinault G, Hara H, Wilkins JJ, Sekiguchi K. Systemic pharmacokinetics of indacaterol, an inhaled once-daily long-acting  $\beta_2$ -agonist, in different ethnic populations. *International Journal of Clinical Pharmacology and Therapeutics*, 2012; 50(8):545-56
13. Brennan BJ, Wang K, Blotner S, Magnusson MO, Wilkins JJ, Martin P, Solsky J, Nieforth K, Wat C, Grippo JF. Safety, tolerability, and pharmacokinetics of ribavirin

in hepatitis C virus-infected patients with various degrees of renal impairment. *Antimicrobial Agents & Chemotherapy* 2013; 57(12):6097-105

14. Wilkins JJ, Dubar M, Sébastien B, Laveille C. A drug and disease model for lixisenatide, a GLP-1 receptor agonist in type 2 diabetes. *Journal of Clinical Pharmacology*, 2014; 54(3):267-78.

## Conference Presentations and Tutorials

1. Wilkins J, Barnes KI, Folb PI. A cost analysis of first-line mild uncomplicated malaria treatment in the Tonga district of Mpumalanga. Proceedings of the MIM African Malaria Conference, 14-19 March 1999, Durban, South Africa. Wellcome Trust, 1999: B-108.
2. Lindbom L, Wilkins JJ, Frey N, Karlsson MO, Jonsson EN. Evaluating the evaluations: resampling methods for determining model appropriateness in pharmacometric data analysis [poster]. PAGE 15 (2006) Abstr 997 [[www.page-meeting.org/?abstract=997](http://www.page-meeting.org/?abstract=997)].
3. Wilkins J, Karlsson MO, Jonsson EN. Patterns and power for the visual predictive check [poster]. PAGE 15 (2006) Abstr 1029 [[www.page-meeting.org/?abstract=1029](http://www.page-meeting.org/?abstract=1029)].
4. Savic RM, Wilkins JJ, Karlsson MO. (Un)informativeness of Empirical Bayes Estimate-Based Diagnostics. In: *The AAPS Journal*; 2006; Vol. 8, No. S2, Abstract T3360
5. Wilkins JJ, Savic RM, Karlsson MO, Langdon G, McIlleron H, Pillai G, Smith PJ, Simonsson US. A flexible approach to modeling variable absorption in the context of repeated dosing: illustrated with rifampicin [oral]. PAGE 16 (2007) Abstr 1113 [[www.page-meeting.org/?abstract=1113](http://www.page-meeting.org/?abstract=1113)].
6. Karlsson KE, Wilkins JJ, Karlsson MO, Jonsson EN. Modelling of disease progression in acute stroke by simultaneously using the NIH stroke scale, the Scandinavian stroke scale and the Barthel index [oral]. PAGE 16 (2007) Abstr 1191 [[www.page-meeting.org/?abstract=1191](http://www.page-meeting.org/?abstract=1191)].
7. Wilkins JJ, Gautier A, Lowe PJ. Bioequivalence, bootstrapping and case-deletion diagnostics in a biologic: a model-based analysis of the effect of formulation differences in a monoclonal antibody [poster]. PAGE 17 (2008) Abstr 1284 [[www.page-meeting.org/?abstract=1284](http://www.page-meeting.org/?abstract=1284)].
8. Wilkins JJ. Census: NLME project management for NONMEM. PAGE 18 (2009) Abstr 1473 [[www.page-meeting.org/?abstract=1473](http://www.page-meeting.org/?abstract=1473)]
9. Wilkins JJ & Looby M. A comparison of two model-based approaches to investigating covariate effects on the dose-exposure relationship in a Phase III context. PAGE 19 (2010) Abstr 1751 [[www.page-meeting.org/?abstract=1751](http://www.page-meeting.org/?abstract=1751)]
10. Wilkins JJ & Jonsson EN. Reproducible pharmacometrics (tutorial). PAGE 22 (2013) Abstr 2774 [[www.page-meeting.org/?abstract=2774](http://www.page-meeting.org/?abstract=2774)]